Midazolam Injection CIV, 10mg/0. 7mL Auto-injector
Closed Pre-Solicitation Posted
- Solicitation number
- SPE2DP-25-R-0007
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Philadelphia, Pennsylvania 19111, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is seeking to procure Midazolam Injection CIV, 10mg/0.7mL Auto-injector units through solicitation SPE2DP-25-R-0007. This medical device is designed for treating status epilepticus in adults and is administered via intramuscular injection through a single-dose, pre-filled autoinjector. The procurement will be conducted as a firm-fixed price, indefinite delivery/indefinite quantity contract with a base year and four one-year option periods. The solicitation is being issued under 10 U.S.C. 2304(c)(1) for only one responsible source, though all responsible sources may submit proposals for consideration. The successful contractor must possess FDA approval to sell Midazolam Injection CIV auto-injectors prior to the solicitation closing date, and the product must meet specifications outlined in MPID Number 1 dated January 31, 2025. The full solicitation is expected to be posted on the DLA Internet Bid Board System around October 2025, with a response due date of October 11, 2025.
This procurement does not utilize any set-aside designation and no current incumbents are identified in the notice. The contract structure includes minimum quantities of 135,000 units per term, annual estimated quantities of 234,240 units per term, and maximum quantities reaching 732,480 units per term across the five-year potential contract duration. Production lead time is established at 180 days after delivery order issuance, with delivery required to DLA Distribution Susquehanna PA in New Cumberland, Pennsylvania. The autoinjectors must have a 36-month expiration date and be stored at temperatures between 20°C to 25°C, with packaging requirements allowing up to 40 single-dose presentations per box. Quality assurance provisions mandate compliance with Good Manufacturing Practices and maintenance of inspection records for three years after delivery, while all products must adhere to Medical Marking Standard 1D for proper labeling and identification throughout the supply chain.
Notice text
Solicitation: SPE2DP-25-R-0007
Item: Midazolam Injection CIV, 10mg/0.7mL Auto-injector
NSN: 6505-31-019-0519
Description:
The Defense Logistics Agency Troop Support has a requirement for the supply of Midazolam Injection CIV, 10mg/0.7mL Auto-injector. The Midazolam Auto-injector shall be made in accordance with MPID Number 1 dated January 31, 2025, which is attached to this notice.
The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1), only one responsible source.
The Government intends to use Part 12 for this acquisition – per FAR 10.002(d)(2).
The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of a base year and four (4) one-year options. The minimum quantity for each term is 135,000 each. The annual estimated quantity for each term is 234,240 each. The maximum quantity for each term is 732,480 each.
Inspection/Acceptance at Destination
FOB Destination
Delivery Destination:
DODDAC: SW3329
DLA Distribution Susquehanna PA
East U Avenue
Bldg. 89, Door 6
New Cumberland, PA 17070-500
Production Lead Time is 180 days after issuance date of the delivery order (DD1155).
All responsible sources may submit a proposal and shall be considered by the Agency.
The successful contractor shall have FDA approval to sell Midazolam Injection CIV, 10mg/0.7mL Auto-injector prior to solicitation closing date.
****************************************************************************
IMPORTANT NOTICES
Availability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-25-R-0007 is expected to be issued in or around October 2025.
Files
| File | Type | Posted |
|---|---|---|
| 25R0007_Midazolam_Synopsis.docx | DOCX document | |
| Midazolam_MPID 1_2025-01-31_FINAL.pdf | ||
| MMS No.1D.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Epinephrine Injector | Medical Supply Chain | No set-aside | |
| Methylphenidate ER | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity